294 related articles for article (PubMed ID: 35408798)
1. EAPB0503, an Imidazoquinoxaline Derivative Modulates SENP3/ARF Mediated SUMOylation, and Induces NPM1c Degradation in NPM1 Mutant AML.
Skayneh H; Jishi B; Hleihel R; Hamie M; El Hajj R; Deleuze-Masquefa C; Bonnet PA; El Sabban M; El Hajj H
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408798
[TBL] [Abstract][Full Text] [Related]
2. Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia.
Nabbouh AI; Hleihel RS; Saliba JL; Karam MM; Hamie MH; Wu HJM; Berthier CP; Tawil NM; Bonnet PA; Deleuze-Masquefa C; El Hajj HA
Cancer; 2017 May; 123(9):1662-1673. PubMed ID: 28055106
[TBL] [Abstract][Full Text] [Related]
3. Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1.
Balusu R; Fiskus W; Rao R; Chong DG; Nalluri S; Mudunuru U; Ma H; Chen L; Venkannagari S; Ha K; Abhyankar S; Williams C; McGuirk J; Khoury HJ; Ustun C; Bhalla KN
Blood; 2011 Sep; 118(11):3096-106. PubMed ID: 21719597
[TBL] [Abstract][Full Text] [Related]
4. Functional regulation of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology.
Vascotto C; Lirussi L; Poletto M; Tiribelli M; Damiani D; Fabbro D; Damante G; Demple B; Colombo E; Tell G
Oncogene; 2014 May; 33(22):2876-87. PubMed ID: 23831574
[TBL] [Abstract][Full Text] [Related]
5. The nucleolar SUMO-specific protease SENP3 reverses SUMO modification of nucleophosmin and is required for rRNA processing.
Haindl M; Harasim T; Eick D; Muller S
EMBO Rep; 2008 Mar; 9(3):273-9. PubMed ID: 18259216
[TBL] [Abstract][Full Text] [Related]
6. When the good go bad: Mutant NPM1 in acute myeloid leukemia.
Kunchala P; Kuravi S; Jensen R; McGuirk J; Balusu R
Blood Rev; 2018 May; 32(3):167-183. PubMed ID: 29157973
[TBL] [Abstract][Full Text] [Related]
7. Mutant NPM1 Maintains the Leukemic State through HOX Expression.
Brunetti L; Gundry MC; Sorcini D; Guzman AG; Huang YH; Ramabadran R; Gionfriddo I; Mezzasoma F; Milano F; Nabet B; Buckley DL; Kornblau SM; Lin CY; Sportoletti P; Martelli MP; Falini B; Goodell MA
Cancer Cell; 2018 Sep; 34(3):499-512.e9. PubMed ID: 30205049
[TBL] [Abstract][Full Text] [Related]
8. HOXBLINC long non-coding RNA activation promotes leukemogenesis in NPM1-mutant acute myeloid leukemia.
Zhu G; Luo H; Feng Y; Guryanova OA; Xu J; Chen S; Lai Q; Sharma A; Xu B; Zhao Z; Feng R; Ni H; Claxton D; Guo Y; Mesa RA; Qiu Y; Yang FC; Li W; Nimer SD; Huang S; Xu M
Nat Commun; 2021 Mar; 12(1):1956. PubMed ID: 33782403
[TBL] [Abstract][Full Text] [Related]
9. Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML.
Pianigiani G; Gagliardi A; Mezzasoma F; Rocchio F; Tini V; Bigerna B; Sportoletti P; Caruso S; Marra A; Peruzzi S; Petito E; Spinozzi G; Shacham S; Landesman Y; Quintarelli C; Gresele P; Locatelli F; Martelli MP; Falini B; Brunetti L
Blood Adv; 2022 Nov; 6(22):5938-5949. PubMed ID: 36037515
[TBL] [Abstract][Full Text] [Related]
10. Could Targeting NPM1c+ Misfolding Be a Promising Strategy for Combating Acute Myeloid Leukemia?
Florio D; Marasco D
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255885
[TBL] [Abstract][Full Text] [Related]
11. Mutant NPM1 Hijacks Transcriptional Hubs to Maintain Pathogenic Gene Programs in Acute Myeloid Leukemia.
Wang XQD; Fan D; Han Q; Liu Y; Miao H; Wang X; Li Q; Chen D; Gore H; Himadewi P; Pfeifer GP; Cierpicki T; Grembecka J; Su J; Chong S; Wan L; Zhang X
Cancer Discov; 2023 Mar; 13(3):724-745. PubMed ID: 36455589
[TBL] [Abstract][Full Text] [Related]
12. NPM1c impedes CTCF functions through cytoplasmic mislocalization in acute myeloid leukemia.
Wang AJ; Han Y; Jia N; Chen P; Minden MD
Leukemia; 2020 May; 34(5):1278-1290. PubMed ID: 31831844
[TBL] [Abstract][Full Text] [Related]
13. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
Falini B; Bolli N; Liso A; Martelli MP; Mannucci R; Pileri S; Nicoletti I
Leukemia; 2009 Oct; 23(10):1731-43. PubMed ID: 19516275
[TBL] [Abstract][Full Text] [Related]
14. Current status and future perspectives in targeted therapy of NPM1-mutated AML.
Ranieri R; Pianigiani G; Sciabolacci S; Perriello VM; Marra A; Cardinali V; Pierangeli S; Milano F; Gionfriddo I; Brunetti L; Martelli MP; Falini B
Leukemia; 2022 Oct; 36(10):2351-2367. PubMed ID: 36008542
[TBL] [Abstract][Full Text] [Related]
15. Non-Mutated Nucleophosmin 1 Is Recognized by the CD8+ T Lymphocytes of an AML Patient after the Transplantation of Hematopoietic Stem Cells from an HLA-Haploidentical Donor.
Nemeckova S; Alexova-Zurkova K; Hainz P; Krystofova J; Mackova J; Roubalova K; Stastna-Markova M; Vrana M; Vydra J
Curr Oncol; 2022 Apr; 29(5):2928-2934. PubMed ID: 35621629
[TBL] [Abstract][Full Text] [Related]
16. Mutant NPM1 Directly Regulates Oncogenic Transcription in Acute Myeloid Leukemia.
Uckelmann HJ; Haarer EL; Takeda R; Wong EM; Hatton C; Marinaccio C; Perner F; Rajput M; Antonissen NJC; Wen Y; Yang L; Brunetti L; Chen CW; Armstrong SA
Cancer Discov; 2023 Mar; 13(3):746-765. PubMed ID: 36455613
[TBL] [Abstract][Full Text] [Related]
17. Actinomycin D Targets NPM1c-Primed Mitochondria to Restore PML-Driven Senescence in AML Therapy.
Wu HC; Rérolle D; Berthier C; Hleihel R; Sakamoto T; Quentin S; Benhenda S; Morganti C; Wu C; Conte L; Rimsky S; Sebert M; Clappier E; Souquere S; Gachet S; Soulier J; Durand S; Trowbridge JJ; Bénit P; Rustin P; El Hajj H; Raffoux E; Ades L; Itzykson R; Dombret H; Fenaux P; Espeli O; Kroemer G; Brunetti L; Mak TW; Lallemand-Breitenbach V; Bazarbachi A; Falini B; Ito K; Martelli MP; de Thé H
Cancer Discov; 2021 Dec; 11(12):3198-3213. PubMed ID: 34301789
[TBL] [Abstract][Full Text] [Related]
18. An atypical GABARAP binding module drives the pro-autophagic potential of the AML-associated NPM1c variant.
Mende H; Khatri A; Lange C; Poveda-Cuevas SA; Tascher G; Covarrubias-Pinto A; Löhr F; Koschade SE; Dikic I; Münch C; Bremm A; Brunetti L; Brandts CH; Uckelmann H; Dötsch V; Rogov VV; Bhaskara RM; Müller S
Cell Rep; 2023 Dec; 42(12):113484. PubMed ID: 37999976
[TBL] [Abstract][Full Text] [Related]
19. Arf-induced turnover of the nucleolar nucleophosmin-associated SUMO-2/3 protease Senp3.
Kuo ML; den Besten W; Thomas MC; Sherr CJ
Cell Cycle; 2008 Nov; 7(21):3378-87. PubMed ID: 18948745
[TBL] [Abstract][Full Text] [Related]
20. Nucleophosmin 1 Mutations in Acute Myeloid Leukemia.
Zarka J; Short NJ; Kanagal-Shamanna R; Issa GC
Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32545659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
